{"id":"intravitreal-ranibizumabe","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Conjunctival hemorrhage"},{"rate":"5-10","effect":"Eye pain"},{"rate":"5-15","effect":"Floaters"},{"rate":"5-10","effect":"Intraocular pressure elevation"},{"rate":"0.05-0.1","effect":"Endophthalmitis"},{"rate":"0.1-0.5","effect":"Retinal detachment"}]},"_chembl":{"chemblId":"CHEMBL1201825","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ranibizumab binds to and neutralizes VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. By inhibiting VEGF-A signaling, it reduces abnormal vessel formation, decreases retinal edema, and slows vision loss in conditions characterized by excessive angiogenesis. The intravitreal route delivers the drug directly to the posterior segment of the eye for local therapeutic effect.","oneSentence":"Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:00.635Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Diabetic macular edema"},{"name":"Retinal vein occlusion (branch and central)"},{"name":"Diabetic retinopathy"},{"name":"Myopic choroidal neovascularization"}]},"trialDetails":[{"nctId":"NCT01246089","phase":"PHASE4","title":"Ranibizumab for Myopic Neovascularization","status":"UNKNOWN","sponsor":"Instituto de Olhos de Goiania","startDate":"2009-07","conditions":"Myopic Choroidal Neovascularization","enrollment":20},{"nctId":"NCT02005432","phase":"PHASE4","title":"PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2012-02","conditions":"Proliferative Diabetic Retinopathy","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Intravitreal Ranibizumabe","genericName":"Intravitreal Ranibizumabe","companyName":"University of Sao Paulo","companyId":"university-of-sao-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye. Used for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion (branch and central).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}